Diagnostics

As the fiber market booms, one brand's two-decade success reveals a powerful link between regenerative agriculture, consumer trust, and digestive wellness.

Genova Diagnostics appoints Keith Meadors as CCO, signaling an aggressive commercial strategy following its recent acquisition of Cell Science Systems.

Spurred by celebrity stories and a viral campaign, the Webby-winning Know Your Lemons app offers personalized risk scores and private screening plans.

A Northeast Georgia cancer center joins an elite national group, offering a cutting-edge 'smart bomb' therapy that brings new hope closer to home for patients.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A $2.5M gift honors a legacy and empowers a top scientist to develop imaging tech that could revolutionize how we diagnose and treat blindness.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

New guidelines advise biennial screening for women 50-74 and caution for others, a move that has drawn sharp criticism from other medical bodies.

New clinical consensus on ammonia and scrutiny of a standard antibiotic are creating a perfect storm for Yaqrit's promising new liver disease treatments.

Beijing's TICSSO-4 conference reveals how single-cell and spatial omics, powered by AI, are accelerating a new era in personalized healthcare.

On World Hemophilia Day, experts reveal over 75% of people with bleeding disorders are undiagnosed, facing a life of pain without access to basic care.

For over a decade, Wake Radiology has backed the Komen Race for the Cure, funding research and expanding access to life-saving breast cancer screenings.

The firm's second consecutive Data Breakthrough Award highlights its success in solving complex, decades-old data challenges for researchers globally.

New data reveals nearly 4 in 10 women lack key vaginal bacteria linked to fertility, sparking a new conversation about an invisible factor in conception.

An FDA-approved system lets surgeons see residual cancer in real-time during lumpectomies, offering new hope for avoiding the dreaded second surgery.

A new survey shows nearly half of employers are considering international drug sourcing, a legally murky strategy, as cost control dethrones talent retention.

GC Biopharma's new data on ALYGLO's purity profile could set a new standard for IVIG therapies, impacting patient safety in a rapidly growing market.

A Boston biotech says its new AI platform moves beyond correlation to find the true biological causes of disease, promising a new era for medicine.

A new DNA-based method for urine drug testing promises to eliminate invasive observation, boosting accuracy while restoring patient dignity. But is it a true revolution?

A new Finnish startup has launched with a tech that could detect cancer years earlier by amplifying protein signals, aiming to shift healthcare to prevention.